These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 36319064)

  • 1. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
    Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
    Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
    Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of immune checkpoint blockade on antigen-specific CD8
    Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
    Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
    Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
    Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients.
    Ma Q; Liu J; Wu G; Teng M; Wang S; Cui M; Li Y
    Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):1002-1009. PubMed ID: 29905955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Jeon SH; You G; Park J; Chung Y; Park K; Kim H; Jeon J; Kim Y; Son WC; Jeong DS; Shin EC; Lee JY; Han DH; Jung J; Park SH
    Clin Cancer Res; 2024 Sep; 30(18):4155-4166. PubMed ID: 38743752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Co-Inhibitory Receptor (Co-IR) Expression on T Cells and Soluble Proteins in Rheumatoid Arthritis.
    Wang CM; Jan Wu YJ; Huang LY; Zheng JW; Chen JY
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
    Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
    Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
    Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
    J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
    He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
    J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
    Huang RY; Eppolito C; Lele S; Shrikant P; Matsuzaki J; Odunsi K
    Oncotarget; 2015 Sep; 6(29):27359-77. PubMed ID: 26318293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054.
    Cebada J; Flores A; Bandala C; Lizaliturri-Flores I; Villa-Ruano N; Perez-Santos M
    Expert Opin Ther Pat; 2020 Jul; 30(7):487-494. PubMed ID: 32397849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
    Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
    Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
    Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
    Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.